{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:12:37Z","timestamp":1778839957715,"version":"3.51.4"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,14]],"date-time":"2027-01-14T00:00:00Z","timestamp":1799884800000},"content-version":"am","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clml.2025.05.021","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T19:48:50Z","timestamp":1748720930000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions | Current and Emerging Novel Treatments for Marginal Zone Lymphoma"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9013","authenticated-orcid":false,"given":"Izidore S.","family":"Lossos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.05.021_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol-20-28","article-title":"Epidemiology of marginal zone lymphoma","volume":"5","author":"Cerhan","year":"2021","journal-title":"Ann Lymphoma"},{"key":"10.1016\/j.clml.2025.05.021_bib0002","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.05.021_bib0003","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/10428194.2021.1984452","article-title":"NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma-opportunities for therapy","volume":"63","author":"Alderuccio","year":"2022","journal-title":"Leukem Lympho"},{"key":"10.1016\/j.clml.2025.05.021_bib0004","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/17474086.2023.2206557","article-title":"Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma","volume":"16","author":"Alderuccio","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2025.05.021_bib0005","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.05.021_bib0006","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: A phase III study of Lenalidomide Plus Rituximab versus Placebo Plus Rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.05.021_bib0007","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood-2022-158631","article-title":"Five-year results and overall survival update from the phase 3 randomized study augment: lenalidomide plus Rituximab (R2) vs Rituximab plus Placebo in patients with relapsed\/refractory indolent non-hodgkin lymphoma","volume":"140","author":"Leonard","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.021_bib0008","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet (Lond Engl)"},{"key":"10.1016\/j.clml.2025.05.021_bib0009","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.021_bib0010","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/ajh.26706","article-title":"A roadmap for clinical trial design in marginal zone lymphoma","volume":"97","author":"Alderuccio","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.05.021_bib0011","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2024-200205","article-title":"Limited duration loncastuximab tesirine induces a high rate of complete responses in patients with relapsed\/refractory marginal zone lymphoma\u2014report of first planned interim futility analysis of a multicenter phase II study","volume":"144","author":"Lossos","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.021_bib0012","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1200\/JCO.18.00138","article-title":"Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution","volume":"36","author":"Alderuccio","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.05.021_bib0013","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/blood.2023020984","article-title":"Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy","volume":"143","author":"Bommier","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.021_bib0014","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.05.021_bib0015","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/cncr.20237","article-title":"Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma","volume":"100","author":"Zinzani","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.05.021_bib0016","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1200\/JCO.2002.05.117","article-title":"Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study","volume":"20","author":"Jager","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.05.021_bib0017","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00277-011-1337-6","article-title":"Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study","volume":"91","author":"Kang","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2025.05.021_bib0018","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S2352-3026(14)00021-0","article-title":"First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial","volume":"1","author":"Salar","year":"2014","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2025.05.021_bib0019","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1002\/cncr.24605","article-title":"Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type","volume":"115","author":"Salar","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.05.021_bib0020","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.021_bib0021","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428190701457949","article-title":"Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma","volume":"48","author":"Lossos","year":"2007","journal-title":"Leukem Lymph"},{"key":"10.1016\/j.clml.2025.05.021_bib0022","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2012.065995","article-title":"A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma)","volume":"98","author":"Kiesewetter","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.05.021_bib0023","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.05.021_bib0024","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1080\/10428194.2020.1802449","article-title":"Long-term outcomes of frontline (90)Y-ibritumomab tiuxetan in marginal zone lymphoma","volume":"61","author":"Lossos","year":"2020","journal-title":"Leukem Lymph"},{"key":"10.1016\/j.clml.2025.05.021_bib0025","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00001622-200309000-00001","article-title":"Update: gastric MALT lymphoma","volume":"15","author":"Kahl","year":"2003","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clml.2025.05.021_bib0026","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.05.021_bib0027","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN Guidelines\u00ae Insights: non-small cell lung cancer, version 2.2023","volume":"21","author":"Ettinger","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2025.05.021_bib0028","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/cancers13081803","article-title":"Treatments and outcomes in stage I extranodal marginal zone lymphoma in the United States","volume":"13","author":"Alderuccio","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2025.05.021_bib0029","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/hon.2334","article-title":"The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma","volume":"35","author":"Laribi","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2025.05.021_bib0030","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjh.15641","article-title":"Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA\/IELSG36 study","volume":"183","author":"Iannitto","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.05.021_bib0031","first-page":"856","article-title":"Rituximab monotherapy for splenic marginal zone lymphoma","volume":"90","author":"Bennett","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.05.021_bib0032","first-page":"194","article-title":"Splenic marginal zone lymphoma: current knowledge and future directions","volume":"26","author":"Thieblemont","year":"2012","journal-title":"Oncology (Willist Park)"},{"key":"10.1016\/j.clml.2025.05.021_bib0033","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/bloodadvances.2021006844","article-title":"An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma","volume":"6","author":"Alderuccio","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.05.021_bib0034","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood-2017-07-795302","article-title":"Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma","volume":"130","author":"Salar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.021_bib0035","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2016-06-720599","article-title":"A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma","volume":"129","author":"Kiesewetter","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.021_bib0036","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/bjh.15843","article-title":"Lenalidomide plus rituximab (R(2)) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial","volume":"185","author":"Becnel","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.05.021_bib0037","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/hon.2647","article-title":"Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-real-world data from the Medical University of Vienna","volume":"37","author":"Kiesewetter","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2025.05.021_bib0038","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000074641","article-title":"Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma","volume":"65","author":"Raderer","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.clml.2025.05.021_bib0039","first-page":"1578","article-title":"Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa","volume":"90","author":"Ferreri","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.05.021_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/2767-9764.CRC-21-0022","article-title":"The genetic landscape of ocular adnexa MALT lymphoma reveals frequent aberrations in NFAT and MEF2B signaling pathways","volume":"1","author":"Magistri","year":"2021","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.clml.2025.05.021_bib0041","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-134363","article-title":"Patients with relapsed\/refractory marginal zone lymphoma in the MAGNIFY Phase IIIb interim analysis of induction R followed by maintenance","volume":"136","author":"Coleman","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.021_bib0042","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.05.021_bib0043","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.18368","article-title":"A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma","volume":"199","author":"Strati","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.05.021_bib0044","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2022-163371","article-title":"Long-term efficacy and safety of Zanubrutinib in patients with relapsed\/refractory (R\/R) marginal zone lymphoma (MZL): final analysis of the Magnolia (BGB-3111-214) trial","volume":"140","author":"Opat","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.021_bib0045","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","article-title":"Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Matasar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.05.021_bib0046","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual PI3K\u03b4\/CK1\u03b5 inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.05.021_bib0047","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/bloodadvances.2023010648","article-title":"A phase 2 study of the PI3Kdelta inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)","volume":"8","author":"Phillips","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.05.021_bib0048","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.05.021_bib0049","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.021_bib0050","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1158\/1078-0432.CCR-21-1704","article-title":"The Magnolia trial: Zanubrutinib, a next-generation bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma","volume":"27","author":"Opat","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2025.05.021_bib0051","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood-2024-194627","article-title":"5-year follow-up analysis from ZUMA-5: a phase 2 trial of Axicabtagene Ciloleucel (Axi-Cel) in patients with relapsed\/refractory indolent non-hodgkin lymphoma","volume":"144","author":"Neelapu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.021_bib0052","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.05.021_bib0053","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after >\/=2 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.021_bib0054","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2025.05.021_bib0055","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.05.021_bib0056","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.05.021_bib0057","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2024-193022","article-title":"Mosunetuzumab with response-driven lenalidomide augmentation As first-line therapy for symptomatic follicular or marginal zone lymphoma: interim analysis of a multi-center phase 2 study","volume":"144","author":"Olszewski","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.021_bib0058","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2024-200190","article-title":"Efficacy and safety of Odronextamab in relapsed\/refractory marginal zone lymphoma (R\/R MZL): data from the R\/R MZL cohort in the ELM-2 study","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.021_bib0059","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2024-194572","article-title":"Safety and efficacy of Rocbrutinib in patients with relapsed\/refractory marginal zone lymphoma","volume":"144","author":"Song","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.021_bib0060","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2024-201646","article-title":"Nemtabrutinib, a noncovalent reversible BTK inhibitor in relapsed or refractory marginal zone lymphoma: results from the phase 2 Bellwave-003 study","volume":"144","author":"Zinzani","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.021_bib0061","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2024-198485","article-title":"A prospective, multicenter, single-arm study on the combination of Orelabrutinib and Rituximab in the second-line treatment of relapsed\/refractory marginal zone lymphoma","volume":"144","author":"Ouyang","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.021_bib0062","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:49:59Z","timestamp":1778838599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2152265025001983"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.021","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Current and Emerging Novel Treatments for Marginal Zone Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}